ID   CHP-100
AC   CVCL_7166
SY   CHP 100; CHP100; Children's Hospital of Philadelphia-100; NB-100
DR   BTO; BTO:0005253
DR   CLO; CLO_0007944
DR   CLDB; cl3642
DR   BioSample; SAMN03151800
DR   cancercelllines; CVCL_7166
DR   Cosmic; 1167419
DR   DSMZ; ACC-830
DR   DSMZCellDive; ACC-830
DR   ECACC; 06122001
DR   GEO; GSM510003
DR   GEO; GSM1676329
DR   GEO; GSM1701661
DR   IARC_TP53; 27037
DR   Progenetix; CVCL_7166
DR   Wikidata; Q54813260
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   PubMed=10079;
RX   PubMed=1992541;
RX   PubMed=2777647;
RX   PubMed=19787792;
RX   PubMed=21822310;
RX   PubMed=26351324;
RX   PubMed=26428435;
RX   PubMed=33460449;
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Misclassified. Originally thought to originate from a neuroblastoma but shown to be from an Ewing sarcoma (PubMed=33460449). Was also partially contaminated as some stocks where shown to be IMR-32 derivatives.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00382.
CC   Doubling time: 45.8 hours (PubMed=10079); ~36 hours (DSMZ=ACC-830).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Hemizygous (PubMed=19787792).
CC   Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=26428435; PubMed=33460449).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792).
CC   Omics: Array-based CGH.
CC   Discontinued: ECACC; 06122001; true.
CC   Derived from site: In situ; Bone, spine, epidural space; UBERON=UBERON_0003691.
ST   Source(s): DSMZ; PubMed=19787792; PubMed=33460449
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 13
ST   D16S539: 10
ST   D18S51: 12,17
ST   D19S433: 13
ST   D21S11: 29
ST   D2S1338: 18,21
ST   D3S1358: 16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 12,15
ST   FGA: 22,25
ST   Penta D: 11,14
ST   Penta E: 11,12
ST   SE33: 17,19
ST   TH01: 6,9.3
ST   TPOX: 8,9
ST   vWA: 17,19 (PubMed=19787792; PubMed=33460449)
ST   vWA: 17,18,19 (DSMZ)
DI   NCIt; C4817; Ewing sarcoma
DI   ORDO; Orphanet_319; Ewing sarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   12Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 27
//
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
//
RX   PubMed=10079;
RA   Schlesinger H.R., Gerson J.M., Moorhead P.S., Maguire H., Hummeler K.;
RT   "Establishment and characterization of human neuroblastoma cell
RT   lines.";
RL   Cancer Res. 36:3094-3100(1976).
//
RX   PubMed=1992541;
RA   Schwachofer J.H.M., Crooijmans R.P.M.A., Hoogenhout H., Kal H.B.,
RA   Schaapveld R.Q.J., Wessels J.;
RT   "Differences in repair of radiation induced damage in two human tumor
RT   cell lines as measured by cell survival and alkaline DNA unwinding.";
RL   Strahlenther. Onkol. 167:35-40(1991).
//
RX   PubMed=2777647; DOI=10.1016/0360-3016(89)90111-9;
RA   Schwachofer J.H.M., Crooijmans R.P.M.A., van Gasteren J.J.M.,
RA   Hoogenhout J., Jerusalem C.R., Kal H.B., Theeuwes A.G.M.;
RT   "Repair of sublethal damage in two human tumor cell lines grown as
RT   multicellular spheroids.";
RL   Int. J. Radiat. Oncol. Biol. Phys. 17:591-595(1989).
//
RX   PubMed=19787792; DOI=10.1002/gcc.20717;
RA   Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S.E.,
RA   Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H.,
RA   Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W.,
RA   Buerger H., Aigner T., Gabbert H.E., Poremba C.;
RT   "Molecular characterization of commonly used cell lines for bone tumor
RT   research: a trans-European EuroBoNet effort.";
RL   Genes Chromosomes Cancer 49:40-51(2010).
//
RX   PubMed=21822310; DOI=10.1038/onc.2011.317;
RA   Mackintosh C., Ordonez J.L., Garcia-Dominguez D.J., Sevillano V.,
RA   Llombart-Bosch A., Szuhai K., Scotlandi K., Alberghini M., Sciot R.,
RA   Sinnaeve F., Hogendoorn P.C.W., Picci P., Knuutila S., Dirksen U.,
RA   Debiec-Rychter M., Schaefer K.-L., de Alava E.;
RT   "1q gain and CDT2 overexpression underlie an aggressive and highly
RT   proliferative form of Ewing sarcoma.";
RL   Oncogene 31:1287-1298(2012).
//
RX   PubMed=26351324; DOI=10.1158/1535-7163.MCT-15-0074;
RA   Teicher B.A., Polley E.C., Kunkel M., Evans D., Silvers T.E.,
RA   Delosh R.M., Laudeman J., Ogle C., Reinhart R., Selby M., Connelly J.,
RA   Harris E., Monks A., Morris J.;
RT   "Sarcoma cell line screen of oncology drugs and investigational agents
RT   identifies patterns associated with gene and microRNA expression.";
RL   Mol. Cancer Ther. 14:2452-2462(2015).
//
RX   PubMed=26428435; DOI=10.1016/j.ejca.2015.08.020;
RA   Sand L.G.L., Scotlandi K., Berghuis D., Snaar-Jagalska B.E., Picci P.,
RA   Schmidt T., Szuhai K., Hogendoorn P.C.W.;
RT   "CXCL14, CXCR7 expression and CXCR4 splice variant ratio associate
RT   with survival and metastases in Ewing sarcoma patients.";
RL   Eur. J. Cancer 51:2624-2633(2015).
//
RX   PubMed=33460449; DOI=10.1002/ijc.33474;
RA   Dirks W.G., Capes-Davis A., Eberth S., Fahnrich S., Wilting J.,
RA   Nagel S., Steenpass L., Becker J.;
RT   "Cross-contamination meets misclassification: awakening of CHP-100
RT   from sleeping beauty sleep -- a reviewed model for Ewing's sarcoma.";
RL   Int. J. Cancer 148:2608-2613(2021).
//